An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)
Terminated
- Conditions
- Colorectal Cancer
- Registration Number
- NCT01276405
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational study will evaluate Xeloda (capecitabine) monotherapy on the effect of disease-free survival in patients with colon cancer stage III (Duke C) after surgical resection. Data will be collected for 3 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 123
Inclusion Criteria
- Adult patients, over the age of 18 years
- Presence of colon adenocarcinoma
- Surgical resection for colon cancer stage III (Duke C)
- Prior adjuvant therapy with Xeloda monotherapy
Read More
Exclusion Criteria
- Contraindications for Xeloda
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease-free survival 3 years
- Secondary Outcome Measures
Name Time Method Safety (Incidence of adverse events) 3 years